Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells

By LabMedica International staff writers
Posted on 17 Jan 2024

Variations in blood cell concentration can be indicative of several health conditions, including infections, inflammatory diseases, malignant blood disorders, and AIDS (Acquired Immune Deficiency Syndrome). More...

Detecting these variations is crucial for diagnosing, treating, and managing these diseases. Traditional methods for measuring blood cell concentration, like using a hemocytometer, typically require an optical microscope. Alternatively, flow cytometers offer a more efficient method for sorting and counting blood cells in fluids, but they are often large and complex, weighing between 9-30 kg, thus limiting their use to laboratory and hospital settings. This restricts the availability of point-of-care testing (POCT) and can delay treatment for patients. Now, a proposed portable smart blood cell analyzer could help overcome the limitations of conventional methods for blood cell concentration detection.

Developed by the Harbin Institute of Technology (HIT, Heilongjiang, China), this innovative analyzer integrates a miniature fluorescence microscope, typically used in neuroscience and behavioral research, with a microfluidic platform. This design significantly reduces the analyzer's size and weight, resulting in a device that measures 35 × 30 × 80 mm and weighs only 39 g, making it substantially lighter than conventional flow cytometers. The analyzer combines image processing with leukocyte counting algorithms to enhance leukocyte information and accurately determine their concentration.

The effectiveness of the proposed analyzer was validated by comparing its leukocyte concentration measurements with those of a standard hemocytometer using Passing-Bablok analysis, achieving a correlation coefficient of 0.979. A Bland-Altman analysis further confirmed the analyzer’s reliability, establishing a 95% limit of agreement ranging from -0.93×10³ to 0.94×10³ cells/μL. The analyzer's error rate in calculating leukocyte concentration was found to be less than 10%, meeting the accuracy standards set by both the UK National External Quality Assessment Service (NEQAS) and the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88). The development of this palm-size optofluidic hematology analyzer is expected to facilitate the POCT of blood cells outside traditional hospital or laboratory settings, thus enhancing medical diagnosis in remote or underserved areas.

Related Links:
HIT


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.